hSLFN13: A Potential Drug Target and Biomarker for Various Diseases

Target Name: SLFN13

NCBI ID: G146857

SLFN13

hSLFN13: A Potential Drug Target and Biomarker for Various Diseases

SLFN13 (hSLFN13), a protein that belongs to the family of small heat shock proteins (hSPP), is a key regulator of the cytoskeleton and plays a crucial role in the development and maintenance of various tissues and organs in the body. hSLFN13 has been identified as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The cytoskeleton is a complex network of filaments and proteins that provides structural support to cells, helps maintain cell shape, and plays a key role in cell movement and division. hSLFN13 is a member of the hSPP family, which includes a variety of cytoskeleton-associated proteins that help maintain cell structure and function. The hSPP family is highly conserved across various species, and many of these proteins have been implicated in a variety of diseases, including cancer.

SLFN13 is a 13-kDa protein that is expressed in a variety of tissues and organs, including muscle, heart, kidney, and brain. It is highly expressed in muscle and heart, and is also found in the brain, where it is involved in the development and maintenance of the myelin sheath surrounding nerve cells. hSLFN13 is also expressed in other tissues, including the placenta, where it may be involved in the regulation of cell death and the formation of new blood vessels.

hSLFN13 has been shown to play a key role in regulating cell division and the cytoskeleton. It is involved in the assembly and disassembly of microtubules, which are important for cell division and transport of organelles within the cell. hSLFN13 has also been shown to regulate the stability of the cytoskeleton, which is important for the proper functioning of the cell and the development of various tissues and organs.

In addition to its role in cell division and the cytoskeleton, hSLFN13 has also been shown to play a role in the regulation of cellular signaling pathways. It is involved in the regulation of the production and degradation of various signaling molecules, including TGF-β, which is a key regulator of cell growth and differentiation. hSLFN13 has also been shown to play a role in the regulation of the immune response, where it is involved in the development and maintenance of immune cells and tissues.

hSLFN13 has been identified as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, hSLFN13 has been shown to be involved in the regulation of cancer cell division and the development of cancer stem cells. It has also been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In addition, hSLFN13 has been shown to be involved in the regulation of autoimmune disorders, where it is involved in the development and maintenance of autoimmune cells and tissues.

hSLFN13 is also a good candidate as a biomarker for cancer, as it has been shown to be upregulated in a variety of cancer types, including breast, lung, and ovarian cancer. It is also expressed in the blood vessels that supply tumors, which may be an indication of the potential for targeting hSLFN13 as a cancer drug.

hSLFN13 may also be a potential drug target for other diseases, including neurodegenerative diseases and autoimmune disorders. For example, hSLFN13 has been shown to be involved in

Protein Name: Schlafen Family Member 13

Functions: Endoribonuclease that cleaves tRNAs and rRNAs (PubMed:29563550). Cleaves tRNAs 11 nucleotides from the 3'-terminus at the acceptor stem (PubMed:29563550). Does not act on tRNA(Sec) (PubMed:29563550). Able to restrict HIV-1 virus replication; ability to inhibit HIV-1 replication is dependent on endoribonuclease activity (PubMed:29563550)

The "SLFN13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLFN13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets